Citation: Kondratyuk M., Hunchak V., Sachuk R. (2026) Clinical efficacy of the use of the preparation “CELEXIB” in the treatment of crucilateral ligament injury of the knee joint in dogs. Veterinary Biotechnology, 48, 108-120. https://doi.org/10.31073/vet_biotech48-07
KONDRATYUK M., 1Postgraduate Student, This email address is being protected from spambots. You need JavaScript enabled to view it., https://orcid.org/0009-0001-4370-0432
HUNCHAK V., 1 Doc. Sci. (Vet. Med.), Prof., This email address is being protected from spambots. You need JavaScript enabled to view it., https://orcid.org/0009-0007-3760-5790
SACHUK R. 2Doc. Sci. (Vet. Med.), Prof., This email address is being protected from spambots. You need JavaScript enabled to view it., https://orcid.org/0000-0003-4532-4220
1Stepan Gzhytskyi National University of Veterinary Medicine and Biotechnologies Lviv
2Rivne State University of the Humanities
CLINICAL EFFICACY OF THE USE OF THE PREPARATION “CELEXIB” IN THE TREATMENT OF CRUCILATERAL LIGAMENT INJURY OF THE KNEE JOINT IN DOGS
Introduction.Injuries of the cruciate ligament of the knee joint in dogs are a common pathology of the musculoskeletal system, accompanied by pain, inflammation and impaired limb function. The effectiveness of the treatment of such injuries largely depends on the use of modern non-steroidal anti-inflammatory drugs, in particular selective cyclooxygenase-2 inhibitors. In this regard, it is relevant to study the clinical efficacy of the drug "Celexib" in the treatment of cruciate ligament injuries in dogs.
Purpose of the work. To establish the clinical efficacy of the drug "Celexib" (solution for injection) in the treatment of cruciate ligament injuries in dogs, as well as to conduct a comparative assessment of its therapeutic effect with the comparator drug "Simaldzheks" according to clinical and clinical-biochemical indicators.
Materials and methods of the study. Clinical studies were conducted on 10 Labrador Retriever dogs aged 6–9 years with injuries of the cruciate ligament of the knee joint in the conditions of veterinary clinics in Rivne. The diagnosis was established on the basis of anamnestic data, clinical examination and radiological examination. The animals were divided into two groups according to the principle of analogues (n=5): the first group was administered the drug "Celexib" intramuscularly, the second was administered the comparison drug "Simaldzheks" orally. The assessment of the effectiveness of the treatment was carried out according to clinical signs and clinical and biochemical blood parameters in dynamics.
Results of research and discussion. In experimental dogs, it was found that the use of complex therapy contributed to the improvement of the general condition of the animals already on the 7th day of treatment. In particular, there was a decrease in edema in the area of the affected joint, which completely disappeared by the 10th day. The animals gradually began to lean on the damaged limb, and the pain reaction significantly decreased. By the 20th day, pain was practically not observed, which indicated a positive recovery dynamics.
A comparative analysis of the effectiveness of the drugs showed that on the 21st day, the level of clinical signs in the first experimental group decreased by 80,0%, while in the second - by 60,0%. Complete clinical recovery of animals in both groups was recorded on the 34th day of the experiment. Both drugs provided pronounced anti-inflammatory and analgesic effects. At the same time, the drug "Celecixib" was not inferior in therapeutic efficacy to the comparison drug.
The results of clinical and biochemical blood tests showed that before treatment, dogs had an increase in the level of leukocytes, total proteins, hexoses and glycosaminoglycans, which indicated an inflammatory process. After the therapy, a significant decrease in these indicators and their approach to physiological limits was observed. In particular, the level of leukocytes decreased by more than 25%, and normalization of protein and carbohydrate metabolism was also noted. The data obtained confirm the effectiveness of the applied treatment regimens and their positive effect on the animal body.
Conclusions and prospects for further research.The use of the drug "Celexib" in the complex therapy of cruciate ligament injury of the knee joint in dogs provides pronounced anti-inflammatory and analgesic effects. It has been established that in terms of clinical efficacy it is not inferior to the comparator drug "Simaldzheks" and promotes the full recovery of animals. The studied drugs have a positive effect on clinical and biochemical blood parameters, which confirms the reduction of the inflammatory process in the body. The prospects for further research are to study the long-term efficacy, safety and optimization of the use regimens of the drug "Celexib" in veterinary practice.
REFERENCES
1. Spinella, G., Arcamone, G., & Valentini, S. (2021). Cranial cruciate ligament rupture in dogs: Review on biomechanics, etiopathogenetic factors and rehabilitation. Veterinary Sciences, 8(9), 186. https://doi.org/10.3390/vetsci8090186.
2. Roush, J. K. (2013). Canine cranial cruciate disease: Updating our knowledge about pathogenesis & diagnosis. Today’s Veterinary Practice, July/August, 16–18.
3. Conzemius, M. (2010). Pathogenesis of cranial cruciate ligament disease in the dog: genetics and anatomy. Proceedings of WVOC 2010, Bologna, Italy.
4. Hermann, M., & Ruschitzka, F. (2007). Cardiovascular risk of cyclooxygenase‐2 inhibitors and traditional non‐steroidal anti‐inflammatory drugs. Annals of Medicine, 39(1), 18–27. https://doi.org/10.1080/07853890601073445
5. McGettigan, P., & Henry, D. (2006). Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA, 296(13). https://doi.org/10.1001/jama.296.13.jrv60011
6. Sachuk, R. M., Hunchak, V. M., & Kondratiuk, M. L. (2025). Doslidzhennia klinichnoi efektyvnosti preparatu «Celekoksib» pry likuvanni artrytiv i artroziv u sobak [Study of the clinical efficacy of celecoxib in the treatment of arthritis and arthrosis in dogs]. Naukovo-tekhnichnyi biuleten Derzhavnoho naukovo-doslidnoho kontrolnoho instytutu veterynarnykh preparativ ta kormovykh dobavok i Instytutu biolohii tvaryn – Scientific and Technical Bulletin of the State Scientific Research Control Institute of Veterinary Medicinal Products and Feed Additives and Institute of Animal Biology, 26(1), 172–181. https://doi.org/10.36359/scivp.2025-26-1.21
7. Kondratiuk, M. L., Hunchak, V. M., & Sachuk, R. M. (2025). Celekoksib yak selektyvnyi inhibitor TsOH-2 u veterynarnii medytsyni: rozrobka ta tekhnolohiia iniektsiinoho preparatu [Celecoxib as a selective COX-2 inhibitor in veterinary medicine: development and technology of an injectable preparation]. Proceedings from the All-Ukrainian Scientific Conference “Na zlami stolit: spadshchyna ta innovatsii v suchasnii veterynarnii farmakolohii i toksykolohii” (Lviv, November 13–14, 2025), 62. https://doi.org/10.32718/konf.13-14.11.2025.
8. Kondratiuk M.L., Hunchak V.M., & Sachuk R.M. (2024). Doslidzhennia hostroi toksychnosti nesteroidnoho protyzapalnoho zasobu dlia sobak na osnovi tselekoksybu. [Acute toxicity study of a nonsteroidal anti-inflammatory drug for dogs based on celecoxib]. Naukovyi visnyk LNUVMB imeni S.Z. Gzhytskoho. Seriia: Veterynarni nauky. 26 (116). 200-205. doi: 10.32718/nvlvet11629 [in Ukrainian].
9. Sachuk, R. M., Hutyi, B. V., Velesyk, T. A., Katsaraba, O. A., Mazur, I. Ya., & Barylo, B. S. (2024). Klinichna efektyvnist zastosuvannia preparatu “Ferodev” pry profilaktytsi ta terapii zalizodefitsytnoi anemii u svynei [Clinical efficacy of the drug “Ferodev” in the prevention and treatment of iron deficiency anemia in pigs]. Naukovo-tekhnichnyi biuleten Derzhavnoho naukovo-doslidnoho kontrolnoho instytutu veterynarnykh preparativ ta kormovykh dobavok i Instytutu biolohii tvaryn – Scientific and Technical Bulletin of the State Scientific Research Control Institute of Veterinary Medicinal Products and Feed Additives and Institute of Animal Biology, 25(2), 138–146. https://doi.org/10.36359/scivp.2024-25-2.17.
10. Kondratiuk A.S., Hrynenko T.V. (2010). Kilkisne vyznachennia fibrynohenu v plazmi krovi turbidymetrychnym metodom z vykorystanniam antsystronu. [Quantitative determination of fibrinogen in blood plasma by turbidimetric method using ancistron]. Fizyka zhyvoho. 18(1).160-163 [in Ukrainian].
11. Kotsiumbas I.Ya., Malyk O.H., Zhyla M.I., & Kosenko Yu.M. (2012). Do pytannia provedennia klinichnykh doslidzhen veterynarnykh likarskykh zasobiv. [On the issue of conducting clinical trials of veterinary medicinal products]. Biolohiia tvaryn. 14 (1-2). S. 34-41 [in Ukrainian].
12. Kotsiumbas I. Ya., Bisiuk, I. Yu., Horzheiev V. M., & O. H. Malyk ta in. (2013). Klinichni doslidzhennia veterynarnykh preparativ ta kormovykh dobavok. [Clinical studies of veterinary drugs and feed additives.]. L. TOV Vydavnychyi dim «SAM». 252 [in Ukrainian].
13. Kotsiumbas I.Ya., Kotsiumbas H.I., & Holubii Ye.M. ta in. (2009). Kompleksna otsinka vplyvu veterynarnykh preparativ na morfofunktsionalnyi stan imunnoi systemy. [Comprehensive assessment of the impact of veterinary drugs on the morphofunctional state of the immune system]. Metodychni rekomendatsii. Lviv. 63 [in Ukrainian].
14. Vlizlo V.V., Fedoruk R.S., & Ratych I.B. ta in. (2012). Laboratorni metody doslidzhennia u biolohii, tvarynnytstvi ta veterynarnii medytsyni: dovidnyk. [Laboratory research methods in biology, animal husbandry and veterinary medicine: a reference book]. Lviv. Spolom. 764 [in Ukrainian].
15. Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European Communities L 358. 1986. 1-29.
16. European convention for the protection of vertebrate animals used for experimental and other scientific purposes. Council of Europe. Strasbourg, 1986. 53.
17. Zakon Ukrainy № 5456-VI vid 16.10.2012. «Pro zakhyst tvaryn vid zhorstokoho povodzhennia». Stattia 26 [in Ukrainian].
18. Kotsiumbas I.Ya, Kosenko Yu.M., Stetsko T.I., & Muzyka V.P. ta in. (2021). Kerivnytstvo shchodo provedennia klinichnykh doslidzhen veterynarnykh preparativ na tsilovykh vydakh tvaryn. [Guidelines for conducting clinical trials of veterinary drugs on target animal species]. Rozrobnyk: Derzhavnyi naukovo-doslidnyi kontrolnyi instytut veterynarnykh preparativ ta kormovykh dobavok. Pereklad i naukovo-tekhnichne redahuvannia. Lviv. 37 [in Ukrainian].
19. Sachuk R.M., Tverdyi Yu.M., Kondratiuk M.L., Kurylas L.V., & Hunchak V.M. ta.in. (2024). Tekhnichni umovy Ukrainy 21.2-40781800-043:2024 «Tseleksyb». DNDKI vetpreparativ ta kormovykh dobavok, Lviv. 25.
20. Statistical principles for veterinary clinical trials. CVMP/EWP/81976/2016.
